Date: 2017-05-30
Type of information: Nomination
Compound: chief medical officer
Company: Alkermes (Ireland)
Therapeutic area: CNS diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 30, 2017, Alkermes announced the appointment of Craig Hopkinson as Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs. Dr. Hopkinson will be responsible for the advancement and implementation of the clinical development programs for Alkermes' pipeline of drug candidates. He will serve on the executive management team of Alkermes and report to Elliot Ehrich, Executive Vice President of Research and Development. Dr. Ehrich will transition his role as Chief Medical Officer to Dr. Hopkinson and will focus on advancing the company's product pipeline and pharmaceutical development strategy.
- Dr. Hopkinson brings more than 20 years of experience building and leading clinical development organizations and medical affairs groups in the biopharmaceutical industry. He has led multidisciplinary development teams in multiple therapeutic areas, including neuroscience, oncology, gastroenterology, infectious diseases, cardiovascular conditions, inflammation, genetic diseases, hematology and neurodegenerative diseases, and has extensive knowledge of clinical study design and the regulatory landscape. Most recently, Dr. Hopkinson held the position of Senior Vice President and Head of Global Medical Affairs for Vertex Pharmaceuticals . Prior to this role, Dr. Hopkinson held various executive management positions at Eisai Pharmaceuticals , including President of Eisai Value Maximization Systems, President and Chief Medical Officer of the Frontier Product Creation Unit, and Vice President of Medical Affairs, Oncology. In addition, Dr. Hopkinson served in leadership positions at Elan Pharmaceuticals , Actelion Pharmaceuticals and Pfizer. Dr. Hopkinson completed his Bachelor of Medicine and Bachelor of Surgery at the University of the Orange Free State in South Africa .
Financial terms:
Latest news:
Is general: Yes
